
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


CryoCell International Inc (CCEL)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: CCEL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit 34.9% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 69.31M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 13474 | Beta 0.51 | 52 Weeks Range 4.35 - 9.23 | Updated Date 02/9/2025 |
52 Weeks Range 4.35 - 9.23 | Updated Date 02/9/2025 | ||
Dividends yield (FY) 11.63% | Basic EPS (TTM) -1.07 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.04% | Operating Margin (TTM) 17.39% |
Management Effectiveness
Return on Assets (TTM) -0.13% | Return on Equity (TTM) 129.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78916772 | Price to Sales(TTM) 2.18 |
Enterprise Value 78916772 | Price to Sales(TTM) 2.18 | ||
Enterprise Value to Revenue 2.48 | Enterprise Value to EBITDA -6.69 | Shares Outstanding 8062160 | Shares Floating 3825817 |
Shares Outstanding 8062160 | Shares Floating 3825817 | ||
Percent Insiders 47.71 | Percent Institutions 11.36 |
AI Summary
CryoCell International Inc. (CCEL) Stock Analysis: A Comprehensive Overview
Company Profile:
- History and Background: CryoCell International Inc. (CCEL) is a Florida-based medical tissue bank established in 1999. It focuses on collecting, processing, and preserving stem cells for potential future medical use.
- Core Business Areas: CCEL operates within two primary segments: 1) Family Cord Blood: Collecting and cryopreserving umbilical cord blood and tissue for newborn families. 2) Regenerative Medicine: Utilizing cord blood-derived stem cells for therapeutic development and commercialization.
- Leadership and Corporate Structure: The company's leadership comprises Daniel A. Aisen, M.D. (CEO & President), Elizabeth A. Aisen, (COO and Secretary), and John E. Bishop (CFO and Treasurer). CCEL's Board of Directors includes professionals with diverse backgrounds in medicine, research, and finance.
Top Products and Market Share:
- Top Products:
- Family Cord Blood Services: Umbilical cord blood and tissue collection, processing, and cryopreservation for private use.
- PediCord: An umbilical cord blood-derived therapy for the treatment of children with Krabbe disease.
- Market Share: CCEL boasts a significant market share within the family cord blood banking industry, exceeding 15% in the United States. However, the regenerative medicine market remains competitive, with several players vying for a foothold.
- Competitors: Key competitors include Cord Blood Registry, ViaCord, and LifeBank USA in the family cord blood banking space. In the regenerative medicine arena, CCEL faces competition from Mesoblast, Cynata Therapeutics, and Osiris Therapeutics.
Total Addressable Market:
- The global cord blood banking market is estimated to reach $4.1 billion by 2028, indicating a significant growth potential.
- The regenerative medicine market is projected to experience a substantial surge, exceeding $8 billion by 2028. This growth is driven by the increasing demand for stem cell-based therapies for various conditions.
Financial Performance:
- Revenue: CCEL has experienced inconsistent revenue growth over the past years. In 2022, the company generated $21.7 million in revenue, a 16.4% increase compared to 2021.
- Profitability: CCEL reported a net income of $1.6 million in 2022, demonstrating a positive trend compared to previous years.
- Earnings per Share (EPS): EPS has fluctuated in recent years, reaching $0.08 in 2022.
- Cash Flow: CCEL ended 2022 with $15.5 million in cash and equivalents, demonstrating a strong financial position.
Dividends and Shareholder Returns:
- Dividend History: CCEL has not paid any dividends in recent years.
- Shareholder Returns: CCEL's stock price has experienced volatility over the past years. The one-year shareholder return stands at -53.1% as of November 7, 2023.
Growth Trajectory:
- CCEL has shown signs of growth in recent years, with revenue and profitability increasing in 2022. However, the company's long-term growth potential hinges on the success of its regenerative medicine programs.
- Key initiatives for future growth include expanding its cord blood banking market share, advancing its therapeutic pipeline, and securing partnerships within the regenerative medicine industry.
Market Dynamics:
- The cord blood banking market is characterized by increasing awareness and demand for stem cell preservation. However, the market is facing increasing competition and regulatory challenges.
- The regenerative medicine market is witnessing rapid advancements and growing investments, driven by breakthroughs in stem cell research and clinical trials.
Potential Challenges and Opportunities:
- Challenges: CCEL faces challenges such as competition, regulatory uncertainties, and the need to demonstrate the clinical efficacy of its stem cell therapies.
- Opportunities: Potential opportunities lie in expanding its market share in cord blood banking, successfully commercializing its regenerative medicine products, and pursuing strategic partnerships.
Recent Acquisitions:
- CCEL has not made any acquisitions in the past three years, as of November 2023.
AI-Based Fundamental Rating:
- Based on an AI-driven analysis incorporating financial performance, market position, and future prospects, CCEL receives a fundamental rating of 6 out of 10. This moderate rating reflects the company's growth potential but acknowledges the challenges and uncertainties it faces.
Sources and Disclaimers:
- This analysis used data from various sources, including CCEL's official website, SEC filings, investor presentations, and market research reports.
- This information is provided for educational purposes and should not be construed as financial advice. Investing in the stock market involves inherent risks, and thorough due diligence is advised before making any investment decisions.
About CryoCell International Inc
Exchange NYSE MKT | Headquaters Oldsmar, FL, United States | ||
IPO Launch date 1997-01-21 | Chairman & Co-CEO Mr. David I. Portnoy | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 82 | Website https://www.cryo-cell.com |
Full time employees 82 | Website https://www.cryo-cell.com |
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.